Table 1 Characteristics of patients with positive anti-mitochondrial antibody and Hepatitis C Virus infection
Characteristics | Patient 1 | Patient 2 | Patient 3 |
|---|---|---|---|
Demographics | |||
Age, yrs | 67 | 63 | 64 |
Sex, M/F | M | F | F |
Anti-Mitochondrial Antibody | |||
Titer by IF at diagnosis | 1:40 | 1:160 | 1:160 |
Liver Enzymes at diagnosis | |||
AP (N<145 IU/L) | 67 | 134 | 71 |
GGT (N<35) | 130 | 330 | 41 |
Hepatitis C Virus | |||
Duration HCV+ status, yrs | 19 | 19 | 15 |
Genotype | 1a | 1a | 4 |
Treatment Naive | Yes | No | Yes |
Treatment Regimen | LDV + SOF | LDV + SOF | SOF +RBV |
RNA NAT, weeks post tx | <12 IU/ml (12) | ND (24) | ND (24) |
Autoantibody Profile (Mitogen) | AMA-M2+, Anti-3E-BPO+ | Anti-3E-BPO+, Anti-Ro52+ | AMA-M2+, Anti-3E-BPO+ |
Fibroscan (fPa) | |||
Pre-treatment with DAA | 37.4 | 15.1 | 14.1 |
Post-treatment with DAA | 19.8 | 12.3 | No data |
Ursodeoxycholic acid treatment | Yes | No (discontinued) | No |